Joseph Walker Reporter
  • New York
  • The Wall Street Journal

Joseph Walker is a New York-based reporter covering the biotechnology and medical device industries.

Focus Areas

  • Biotechnology
  • Medical Device Industry

123 Articles
7 days ago
wsj.com

Newest Alzheimer’s Drugs Take Large But Fraught Step Toward Approval

Positive study results for Eisai-Biogen lifted the prospects for its medication and one from Eli Lilly—although regul...

Read Full Article
8 days ago
wsj.com

New Alzheimer’s Drug Shows Positive Results but Side Effects

The drug from Eisai and Biogen slowed cognitive decline in study volunteers, but many had brain bleeds, swelling or o...

Read Full Article
28 days ago
wsj.com

Biogen Names Christopher Viehbacher New CEO

The veteran pharmaceutical executive takes charge of after the failed launch of Biogen’s once-promising Alzheimer’s d...

Read Full Article
about 1 month ago
wsj.com

Cardinal Health Quarterly Sales Up 13%

Cardinal Health Inc. said its top line rose 13% in its recently completed quarter, with gains for its pharmaceutical ...

Read Full Article
about 1 month ago
wsj.com

RSV Vaccine Protected Infants From Severe Cases, Pfizer Study Finds

Pfizer said the results were sufficient to seek approval for its shot, which could be the first deployed against the ...

Read Full Article
about 1 month ago
wsj.com

Volunteer Dies Testing Eisai-Biogen Alzheimer’s Drug During Study

The subject experienced swelling and bleeding in the brain, an Eisai spokeswoman said. It wasn’t clear if the death w...

Read Full Article
about 1 month ago
wsj.com

Biotech Co-Founder, Facing Murder-for-Hire Charges, Accused of Fabricating Data

Enochian BioSciences Inc. has sued co-founder Serhat Gumrukcu for contractual fraud, alleging that it paid him and hi...

Read Full Article
2 months ago
wsj.com

Amylyx’s ALS Drug Is Approved by the FDA

The medicine, called Relyvrio, gives patients with the degenerative disease a new treatment option, but some FDA staf...

Read Full Article
2 months ago
wsj.com

Alzheimer’s Drug Slows Disease Progression in Trial

Eisai and Biogen said their experimental Alzheimer’s drug significantly slowed progression of the memory-robbing dise...

Read Full Article
2 months ago
wsj.com

Biogen Agrees to Pay $900 Million Over Alleged Improper Physician Payments

The pharmaceutical company settled allegations that it paid kickbacks to doctors to induce them to prescribe the comp...

Read Full Article
3 months ago
wsj.com

Swedish Biotech’s Cancer Drug Fails With FDA Advisers

The negative vote dims chances for Oncopeptides’s treatment to return to the market, after the company pulled it in O...

Read Full Article
3 months ago
wsj.com

Crispr Gene-Editing Drugs Show Promise in Preliminary Study

Intellia Therapeutics said two of its experimental Crispr treatments produced positive results in early-stage trials.

Read Full Article

Copyright © 2021 All rights reserved. Legitimate Limited.